Hepatocytes are an important tool for in vitro toxicology testing. In addition to primary cultures, a limited number of immortalized cell lines have been developed. We here describe a new cell line, designated as HepaMN, which has been established from a liver associated with biliary atresia.
Background
The liver is essential for maintaining normal physiology and homeostasis and is composed of hepatocytes, endothelial cells, and stellate cells. Among these cells, hepatocytes play a key role in metabolism and detoxification. However, human hepatocytes are difficult to propagate ex vivo due to lack of appropriate cultivation conditions. To solve this issue, hepatocytes have been freshly isolated from livers, generated from hepatomas, induced from pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), and converted from other somatic cells such as fibroblasts (1) (2) (3) (4) (5) (6) . However, a steady supply of hepatocytes dissociated from livers for use as in vitro models cannot be guaranteed because of limited supply and lot-to-lot variations due to genetic and environmental backgrounds.
Likewise, iPSC-or ESC-derived hepatocytes may show variation between lots, due to the difficulty of strictly controlling the differentiation process (7) . Even when hepatocytes are generated from a bank of undifferentiated iPSCs or ESCs, the direct reprogramming technology requires complex protocols and a relatively long period for complete differentiation, and yields a limited number of mature hepatocytes among a heterogeneous population (8, 9) . HepG2, a hepatoblastoma cell line, exhibits hepatocyte-like features with a limited expression of hepatocyte-associate markers such as albumin and cytochrome P450 (CYP) (10) . Likewise, HepaRG, a spontaneously immortalized cell line, from hepatocarcinoma of a female patient has more hepatic features compared to HepG2 (11) .
Immortalized hepatocytes derived from normal hepatocytes would be ideal to ensure of a steady supply. Immortalized hepatic cell lines have advantages such as formation of large lots, in vitro propagation, genetic and environmental uniformity, and a lack of ethical concerns, compared with cryopreserved isolated hepatocytes and primarily cultivated hepatocytes. From this viewpoint, HepG2 and HepaRG cells have been extensively used for evaluating the toxicity of chemicals and drugs. HepaRG has been used for CYP induction studies, especially induction of CYP3A4, because more than half of all small-molecule drugs commonly used by humans are metabolized by CYP3A4, and inhibition of CYP3A4mediated metabolism is a common cause of drug-induced liver injury. In this study, we generated an immortalized hepatocyte cell line, HepaMN, from a Japanese patient with biliary atresia. We applied a previously used strategy for immortalization of human keratinocyte or mammary epithelial cells -inactivation of the Rb/p16 pathway and acquisition of telomerase activity (12) . HepaMN cells constitutively exhibited a hepatocytic phenotype both in vitro and in vivo, and showed increased CYP3A4 after exposure to rifampicin, implying that HepaMN cells are a suitable tool for pharmaceutical studies.
Methods

Viral vector construction and viral transduction
Construction of the lentiviral vector plasmids CSII-CMV-Tet-Off, CSII-TRE-Tight-cyclin D1, and CSII-TRE-Tight-CDK4R24C was previously described (13) . In brief, the EF1a promoter in CSII-EF-RfA (a gift from Dr. H. Miyoshi, RIKEN, presently Keio University) was replaced with a tetracycline-inducible promoter, TRE-Tight, from pTRE-Tight (Clontech, Mountain View, CA) to generate CSII-TRE-Tight-RfA. Human cyclin D1, human mutant CDK4 (CDK4 R24C : an INK4a-resistant form of CDK4), and TERT were inserted into the entry vector via a BP reaction (Invitrogen, Carlsbad, CA). These segments were then recombined with CSII-TRE-Tight-RfA through an LR reaction (Invitrogen) to generate CSII-TRE-Tight-cyclin D1, CSII-TRE-Tight-CDK4R24C, and CSII-TRE-Tight-TERT. The rtTA segment from pTet-Off Advanced (Clontech) was amplified by PCR, recombined with the donor vector pDONR221 via a BP reaction (Invitrogen) to generate pENTR221-Tet-Off, and then recombined with a lentiviral vector, CSII-CMV-RfA, through an LR reaction (Invitrogen) to generate CSII-CMV-Tet-Off. Recombinant lentiviruses with vesicular stomatitis virus G glycoprotein were produced as described previously (14) . Primary hepatocytes were inoculated with CSII-CMV-TERT, CSII-CMV-Tet-Off, CSII-TRE-Tightcyclin D1 and CSII-TRE-Tight-CDK4R24C lentiviruses at the multiplicity of infection of 3 to 10 in the presence of 4 micrograms/mL of polybrene.
Human Cells
The cells were isolated from a liver of 4-year-old girl with biliary atresia (Hep2018). The hepatocytes were isolated according to the collagenase perfusion method, as described elsewhere (1 (13) . Cells proliferated constantly after infection, and were frozen at passage 3. These cells were maintained in the ESTEM-MN medium, and the medium was renewed every 2 or 3 days, and were passaged every 1 week (1/5 dilution) by trypsinization.
Cell culture
HepaMN cells were passaged every 1 week (1/5 dilution) by trypsinization. HepaMN cells were maintained for 1 weeks in the ESTEM-MN medium (GlycoTechnica Ltd.) at 37℃ in 5% CO2, and the ESTEM-MN medium was renewed every 2 or 3 days.
Calculation of population doublings
Primary hepatocytes and HepaMN cells were seeded at 0.8 to 1.0 x 10^6 cells/well in a 100mm dish. When the cells reached subconfluent, both primary cells and HepaMN cells were harvested and the total number of cells in each well was determined using the cell counter.
Population doubling (PD) was used as the measure of the cell growth rate. PD was calculated from the formula PD ¼ log2 (A/B), where A is the number of harvested cells and B is the number of plated cells.
Immunoblotting
Whole-cell protein extracts were used for analysis, and immunoblotting was conducted as described previously (15) . Antibodies against CDK4 (clone D9G3E; Cell Signaling Technology, Danvers, MA), CyclinD1 (clone G124-326; BD Biosciences, Franklin Lakes, NJ), GAPDH (clone 6C5, Ambion), p16INK4a (clone G175-405, BD Biosciences) were used as probes, and horseradish peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulins (Jackson Immunoresearch Laboratories, West Grove, PA) were employed as secondary antibodies. The LAS3000 charge-coupled device (CCD) imaging system (Fujifilm Co. Ltd., Tokyo, Japan) was employed for detection of proteins visualized by Lumi-light Plus Western blotting substrate (Roche, Basel, Switzerland).
Histological analysis of HepaMN
HepaMN cells were harvested with a cell scraper and collected into tubes. The cells were analyzed with an iPGell kit (GenoStaff, Tokyo, Japan).
Immunocytochemical analysis
HepaMN cells were fixed in 4% paraformaldehyde for 10 min at 4°C. After washing with PBS and treatment with 0.1% Triton-X for 10 min at room temperature, cells were preincubated with blocking buffer (1% BSA in PBS) for 30 min at room temperature, and then reacted with primary antibodies in blocking buffer for 12 h at 4°C. Followed by washing with PBS, cells were incubated with secondary antibodies; anti-goat or anti-mouse IgG conjugated with Alexa 488 or 546 (1:1000) (Invitrogen) in blocking buffer for 30 min at room temperature. Then the cells were counterstained with DAPI and mounted.
Karyotypic analysis
Karyotypic analysis was contracted out at Nihon Gene Research Laboratories Inc. (Sendai, Japan). Metaphase spreads were prepared from cells treated with 100 ng/mL of Colcemid (Karyo Max, Gibco Co. BRL) for 6 h. The cells were fixed with methanol:glacial acetic acid (2:5) three times, and dropped onto glass slides (Nihon Gene Research Laboratories Inc.).
Chromosome spreads were Giemsa banded and photographed. A minimum of 10 metaphase spreads were analyzed for each sample, and karyotyped using a chromosome imaging analyzer system (Applied Spectral Imaging, Carlsbad, CA).
Quantitative RT-PCR
RNA was extracted from cells using the ISOGEN (NIPPON GENE). An aliquot of total RNA was reverse transcribed using an oligo (dT) primer (SuperScript TM Ⅲ
First-Strand Fluorescence was monitored during every PCR cycle at the annealing step. The authenticity and size of the PCR products were confirmed using a melting curve analysis (using software provided by Applied Biosystems) and gel analysis. mRNA levels were normalized using ubiquitin or GAPDH as a housekeeping gene.
Gene chip analysis
High quality total RNA was isolated from each cell using Trizol® following the manufacturer's instructions (Invitrogen, USA). Genomic DNA was eliminated by treatment with DNAse I for 20 min at RT using DNAse IH (Invitrogen, USA). RNA concentration was measured using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, Delaware USA). Purity and integrity of total RNA was determined by 260/280 nm ratio and checked by electrophoresis in Bioanalyzer RNA6000 Nano. About 100 ng of total RNA was used to produce Cyanine 3-CTP labeled cRNA using the Low Input Quick Amp Labeling Kit, One-Color (Agilent Technologies) according to the manufacturer's instructions. Following 'One-Color Microarray Based Gene Expression Analysis' protocol version 6.0 (Agilent Technologies), 2 μ g of labeled cRNA was hybridized with a human gene expression microarray 60K (Agilent Technologies, Santa Clara CA, USA). The microarray workflow quality control was implemented using the Agilent Spike-In Kit which consisted of a set of 10 positive control transcripts optimized to anneal to complementary probes on the microarray with minimal self-hybridization or cross-hybridization. The concentrated Agilent
One-Color RNA Spike-In mix stock was diluted in the buffer provided by the kit and mixed with the RNA samples prior to the amplification and labeling process to achieve the relative amounts recommended by the manufacturer.
For hybridization, Agilent gene expression microarray 60K slide (Design ID: 72363.
SurePrint G3 Human Gene Expression 8 x 60K Microarray Kit, Agilent Technologies) were used. Slides were scanned in an Agilent C Scanner according to the manufacturer's protocol.
Signal data were collected with dedicated Agilent Feature Extraction Software (v 11.5.1).
Agilent Processed Signals were processed using GeneSpring software (Agilent Technologies).
Principal component analysis (PCA)
To analyze the expression data of genes in an unsupervised manner with a gene chip array, we used principal component analysis (16, 17) . PCA, a multivariate analysis technique which finds major patterns in data variability, was performed to categorized HepaMN cells into each stage of ESCs undergoing hepatic differentiation. The differentiation protocol was previously reported in detail (18) . 
In vivo analysis
The operation protocols were approved by the Laboratory Animal Care and the Use were subcutaneously inoculated into severe combined immunodeficiency (SCID) mice (CREA, Tokyo, Japan). After 9 days, the resulting tumors were dissected and fixed with PBS containing 4% paraformaldehyde. Paraffin-embedded tissue was sliced and stained with hematoxylin and eosin (HE). HepaMN cells were also implanted into spleen in immunodeficient SCID mice. HepaMN cells were harvested with a cell scraper, collected into tubes, centrifuged, and resuspended in PBS (50 μ l). The cells (> 1 x 10 6 ) were intrasplenically implanted. After 7 days, the spleens were dissected and fixed with PBS containing 4% paraformaldehyde for further histological analysis.
Immunohistochemistry
Subcutaneous nodules on mouse backs were fixed in 20% formalin and embedded in paraffin.
Cut paraffin sections were deparaffinized, dehydrated, and treated with 2% proteinase K 
CYP3A4 induction test
Statistical analysis
Statistical analysis was performed using the unpaired two-tailed Student's t test. HepaMN cells reproducibly proliferated more rapidly than the primary cells as determined by population doubling values ( Figure 1G ). HepaMN cells continued to expand, and neither cessation of cell proliferation, such as senescence nor apoptosis/cell death, was detected during cultivation through 21 passages (141 days), implying that the hepatocytes were immortalized by the introduction of CDK4 R24C , cyclin D1, and TERT genes ( Figure 1H ). We performed immunoblot analysis of CDK4 and cyclin D1 to confirm the expression of the transgenes ( Figure 1I ). We found that CDK4 and cyclin D1 were highly expressed, and suppressed by doxycycline treatment. To determine TERT, we performed a TRAP assay in a series of hepatocytes infected with the TERT gene ( Figure 1J ). The results clearly show that the TERT infection resulted in the induction of enzyme activity. We also performed karyotypic analysis of HepaMN cells. HepaMN cells had a normal karyotype (7 out of 20 metaphases) and chromosome 2 trisomy (9 out of 20 metaphases) at passage 16 ( Figure 1K , L, M).
Results
Generation of HepaMN cells
Characterization of HepaMN cells in vitro
Immunocytochemistry revealed that HepaMN cells were positive for albumin and epithelial keratins (Figure 2A 
Hepatocyte-associated gene expression in HepaMN cells
Global outlook by principal component analysis (PCA)
To clarify the differentiated state of HepaMN, we compared the gene expression levels in HepaMN cells and hepatocyte-differentiated ESCs using Agilent Technologies GeneChip oligonucleotide arrays.
LGR5XF32d30 and LGR5XF32d60 used in this study are human ESCs that were differentiated into hepatocytes for 30 and 60 days, respectively. We then performed PCA from the expression data of liver-associated genes, i.e. developing and mature hepatocyte markers (Supplemental Table 2 ). PCA based on liver-associated genes demonstrated that HepaMN cells are grouped into the category that includes embryonic stem cell-derived terminally differentiated hepatocytes (circled in red and green in Figure 3J and 3K, respectively). The genes on the PC1 axis, based on developing and mature hepatocyte markers, are listed with correlations in Table 1A and B, respectively. These similarities led us to hypothesize that HepaMN cells maintain a specific differentiated state that strongly resembles hepatocytes.
In vivo analysis of HepaMN cells
To address whether HepaMN cells exhibit hepatocytic phenotypes in vivo, they were injected into subcutaneous tissue (1.0 to 5.0 x 10 7 cells/site) of immunodeficient SCID mice ( Figure   4A 
Measurement of cytochrome P450 (CYP) mRNA induction after drug treatment
In order to examine HepaMN cells for CYP induction, HepaMN cells were exposed to omeprazole, phenobarbital, or rifampicin ( Figure 5A ). CYP3A4 and CYP1A2 were induced with exposure to rifampicin 8. 
Discussion
To date, HepaRG is the best hepatocyte line for drug interaction studies and hepatitis virus infection. We herewith introduce a novel hepatocyte line, HepaMN, that was established from a patient with biliary atresia, a childhood disease of the liver in which bile ducts are abnormally narrow or absent. While HepaRG and HepG2 were generated from hepatoma or 
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Supplemental Figure 2. Gene induction test for CYP1A1 and CYP1A2 in HepaMN cells
Quantitative RT-PCR analysis of the genes for CYP1A1 and CYP1A2 was performed on
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